Sarepta Therapeutics lays off 493 workers amid FDA probe, stock drop, and concerns over its gene therapy treatment, Elevidys.

Sarepta stock crashed Friday on reports the FDA will ask the biotech company to stop shipments of its approved gene therapy, ...

Sarepta Therapeutics shares surged 34% in after-hours trading on Wednesday after the company said it would slash 500 jobs, or ...

The death of a third patient tied to a Sarepta Therapeutics gene therapy this year sent the company’s shares nosediving 36% Friday, halting the momentum the stock generated just a day earlier after ...

Sarepta rebuffed a call from the Food and Drug Administration to halt all shipments of its gene therapy for Duchenne muscular ...

Sarepta's stock has declined 20.2% so far this year, in line with a 21.1% decline in the S&P 500 index. [s:spx] Show Conversation (0) Partner Center. Most Popular. Advertisement.

What happenedShares of Sarepta Therapeutics (NASDAQ: SRPT) were crashing 50.7% as of 11:11 a.m. EST on Friday. The huge decline came after the biotech announced top-line results late on Thursday ...

The stock price of Sarepta Therapeutics (NASDAQ:SRPT), a biotech company focused on the discovery and development of RNA-targeted therapeutics and gene therapy for the treatment of rare diseases ...

Carving out $400 million in annual cost savings is going over well with Sarepta Therapeutics Inc.’s investors, as the company’s stock got a 19.6% boost on July 17. Its big seller, the gene therapy ...

Looking at a longer time period, SRPT stock is actually down 35% from levels seen toward the end of 2018. The decline in stock price over the last two years or so can be attributed to unfavorable ...

Sarepta Therapeutics stock declined 14% over the last five trading days (one week), compared to broader market (S&P500) decline of 0.03%; A change of -14% or more over five trading days (one week ...